Gilead Sciences (GILD) Set to Acquire Arcellx
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polaris Capital Management Bernard Horn | 252,200 | $35,149,114 | -5% | 2.88% |
| 2. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 8,390 | $1,169,314 | -12% | 0.59% |
| 3. | Ayrshire Capital Management John Nevin Jr. | 5,400 | $752,598 | 0.39% | |
| 4. | Sivik Global Healthcare Krishen Sud | 25,000 | $3,484 | 2.65% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $140.96 | 3,000 | $422,880.00 | 176,191 | 2026-04-15 | Filing | |
| $140.96 | 3,000 | $422,880.00 | 128,779 | 2026-04-15 | Filing | |
| $136.82 | 10,000 | $1,368,162.00 | 642,567 | 2026-03-27 | Filing | |
| $144.23 | 3,000 | $432,690.00 | 131,779 | 2026-03-16 | Filing | |
| $144.23 | 3,000 | $432,690.00 | 179,191 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,354,394 | $467,501,890 | 0.67% | |
| 2. | 2,574,822 | $356,943,033 | 0.38% | |
| 3. | 1,811,223 | $252,430,149 | 0.37% | |
| 4. | 861,023 | $120,000,813 | 1.86% | |
| 5. | 824,573 | $114,920,781 | 0.35% |
News See All
8 Best Stem Cell Therapy Stocks to Buy
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...
14 Best Defensive Stocks to Invest In Now
The US economy has entered the final week of April navigating a precarious war-driven landscape that has fundamentally altered the outlook for both growth and monetary policy.
Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings
TheFly reported on April 10 that Morgan Stanley increased its price target for GILD to $175 from $171 while maintaining an Overweight rating.
Jim Cramer’s 11 Stocks Review: HOOD, WFC, and Market Rotation
In this article, we will look at the stocks Jim Cramer reviewed on Mad Money while discussing the recent market rotation.
10 Best Healthcare Stocks to Buy and Hold for 3 Years
The first quarter of this year has seen a great deal of volatility in the equity markets. The S&P 500 fell into correction territory before rising again after first soaring to all-time highs.
10 Healthcare Stocks with Highest Dividends
In December, CNBC reported that health-care job growth is propping up the labor market at a time when many other industries are struggling.
13 NASDAQ Stocks with Highest Dividends
In recent years, technology markets have drawn more attention from investors around the world, especially those linked to the NASDAQ Composite Index.
8 Best Quality Stocks to Buy According to Hedge Funds
On April 9, Tom Lee of Fundstrat appeared on CNBC's 'Closing Bell' to suggest that the market has reached a bottom.
7 Most Profitable Value Stocks to Buy Right Now
On April 2, Kevin Mahn, Hennion & Walsh Asset Management president and chief investment officer, joined 'Squawk Box' on CNBC to discuss market reactions to developments in the Iran war.
Hedge Fund Resource Center